AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19635606
Drug: Recombinant interferon-alpha2b
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon-alpha2b (IFN) as an adjuvant to HBV vaccine
Trial: 11146393
Drug: HBV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccine alone
Trial: 17111013
Drug: Carbohydrate supplementation
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplementation (1 g.kg body mass(‐1))
Trial: 16900304
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment (ACT, social skills training, and family intervention)
Trial: 11815428
Drug: Fosinopril 40
RxNorm normalized name: fosinopril 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril 40 mg
Trial: 11329095
Drug: Fosinopril 1
RxNorm normalized name: fosinopril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril 1 mg
Trial: 11329095
Drug: Fosinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (20 mg and 40 mg)
Trial: 2191878
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g acetylsalicylic acid (ASA) per day, starting day two prior to surgery
Trial: 2191878
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without antiplatelet medication
Trial: 2191878
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g acetylsalicylic acid (ASA) in patients with signs of progression in histopathological examination
Trial: 76397
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate tablets, 0.6 g daily for 4 weeks
Trial: 25251189
Drug: High COHb
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High COHb (≥4 g·dl(‐1))
Trial: 25251189
Drug: Low COHb
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low COHb (≤3 g·dl(‐1))
Trial: 16409323
Drug: sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile saline solution + Hybrid technique
Trial: 16409323
Drug: sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile saline solution + NiTi rotary technique 4 mm shorter than the apex
Trial: 16409323
Drug: sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile saline solution + NiTi rotary technique (Hero 642)
Trial: 9489432
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (NED) 8mg twice daily
Trial: 8384073
Drug: Low-dose craniospinal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose craniospinal radiation therapy (1800 cGy) plus chemotherapy (vincristine during RT, followed by vincristine, cisplatin, and lomustine for eight cycles every 6 weeks)
Trial: 8384073
Drug: Low-dose craniospinal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose craniospinal radiation therapy (1800 cGy) plus chemotherapy
Trial: 2936841
Drug: Oral instruction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral instruction from physician and clinical nurse specialist
Trial: 29115703
Drug: Sertraline (SRT)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (SRT) at 200 mg
Trial: 25709987
Drug: Granisetron 3
RxNorm normalized name: granisetron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 3 mg iv 2 minutes before induction of anesthesia
Trial: 25709987
Drug: Oral gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral gabapentin 300 mg 1 hour before anesthesia
Trial: 21415104
Drug: Selenium (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (500 μg/day)
Trial: 21415104
Drug: Glutamine (20.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (20.2 g/day)
Trial: 12752541
Drug: Mandibular implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular implant overdentures (IOD)
Trial: 11922148
Drug: Diet and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet and oral hypoglycaemic drug (Daonil) therapy
Trial: 9725753
Drug: Halcion (triazolam)
RxNorm normalized name: triazolam Oral Tablet [Halcion]
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Halcion (triazolam) 0.375 mg p.o.
Trial: 31242139
Drug: Contrast water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast water therapy
Trial: 21309657
Drug: Aspirin (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (81 to 324 mg per day)
Trial: 2064065
Drug: Lumbar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar epidural morphine 5 mg
Trial: 2064065
Drug: Lumbar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar epidural nalbuphine 10 mg
Trial: 2064065
Drug: Lumbar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar epidural nalbuphine 20 mg
Trial: 6321426
Drug: Imipenem with
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Imipenem with cilastatin, 500 mg/500 mg iv tid
Trial: 6321426
Drug: Cefotaxime, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime, 2 g iv tid
Trial: 30564847
Drug: Paravertebral block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral block (Pv, n=20) with 20 ml 0.25% bupivacaine at the level of T8-T9
Trial: 30564847
Drug: Peritubal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritubal infiltration (Pi, n=20) with 20 ml 0.25% bupivacaine along the nephrostomy tube
Trial: 30339623
Drug: Patch repair
RxNorm normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch repair (PROCEED Ventral Patch)
Trial: 22926233
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg/d
Trial: 23380218
Drug: Fluticasone 250
RxNorm normalized name: FLUTICASONE 250MCG/BLSTR PO INH ROTADISK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone 250 μg twice daily
Trial: 15619331
Drug: Tailor-made treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailor-made treatment program addressing biopsychosocial factors
Trial: 10620554
Drug: Recombinant tissue
RxNorm normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant tissue plasminogen activator (rTPA) 2 mg
Trial: 10620554
Drug: Heparin 2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin 2,000 IU
Trial: 8648870
Drug: Tricyclic antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressants (imipramine or desipramine)
Trial: 8648870
Drug: Fluoxetine, Tricyclic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine, Tricyclic antidepressants
Trial: 1335647
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (720 ELISA units)
Trial: 1335647
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine (20 micrograms)
Trial: 1335647
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of hepatitis A and B vaccines
Trial: 6100260
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg dose)
Trial: 6100260
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no drug administration)
Trial: 3033966
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine (30 mg slow-release preparation)
Trial: 3033966
Drug: Naloxone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (4 mg bolus iv)
Trial: 3033966
Drug: Naloxone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (4 mg iv bolus followed by continuous infusion of 6 mg over 75 min)
Trial: 3033966
Drug: Placebo (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for both morphine and naloxone protocols)
Trial: 25622666
Drug: 270 mgI/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 270 mgI/ml low concentrations of contrast agents and spectral CT imaging (Group A)
Trial: 25622666
Drug: 350 mgI/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mgI/ml high concentrations of contrast agents and 120 kVp scan (Group B)
Trial: 18721899
Drug: High-dose fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fish oil (9600 mg of fish oil/day, 2880 mg of n-3 fatty acids)
Trial: 14576512
Drug: hANP (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hANP (initial dose: 0.025 microg/kg/min, maximum dose: 0.035 +/- 0.019 microg/kg/min)
Trial: 14576512
Drug: Control (nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (nicardipine hydrochloride; 4.41 +/- 1.68 mg/h)
Trial: 8677571
Drug: Neoadjuvant MVAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant MVAC chemotherapy
Trial: 8677571
Drug: Adjuvant MVAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant MVAC chemotherapy
Trial: 2233115
Drug: Diltiazem 90
RxNorm normalized name: diltiazem 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 90 mg twice daily
Trial: 7340890
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg once daily
Trial: 27059799
Drug: Clazakizumab 100
RxNorm normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab 100 mg
Trial: 27059799
Drug: Clazakizumab 25
RxNorm normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab 25 mg
Trial: 27059799
Drug: Clazakizumab 200
RxNorm normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab 200 mg
Trial: 27059799
Drug: Clazakizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazakizumab (all doses)
Trial: 22507276
Drug: Two-strain combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-strain combination probiotic (Lactobacillus acidophilus and Bifidobacterium bifidum) given twice a day for 3 months
Trial: 22507276
Drug: Placebo given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given twice a day for 3 months
Trial: 22507276
Drug: Two-strain combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-strain combination probiotic
Trial: 18628618
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg/day) for 14 days
Trial: 18628618
Drug: L-arginine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (500 microM)
Trial: 18628618
Drug: L-N(5)-(I-iminoethyl)ornithine (NOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-N(5)-(I-iminoethyl)ornithine (NOS inhibitor)
Trial: 11315826
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker (amlodipine)
Trial: 8722437
Drug: Alpha-adrenergic blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-adrenergic blocker (doxazosin)
Trial: 9326656
Drug: Oral pyrimidine
RxNorm normalized name: 4'-Hydroxypyrazolol(3,4-d)pyrimidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pyrimidine nucleoside or nucleotide compounds
Trial: 21356082
Drug: Micronutrients capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrients capsule (zinc 30 mg, selenium 70 μg, vitamin A 400 μg, alpha-tocopherol 30 mg, vitamin C 200 mg, niacin 100 mg)
Trial: 19245076
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment in a hyperbaric chamber
Trial: 11672947
Drug: Social distribution
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social distribution of drug use
Trial: 9039532
Drug: High-dose clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clarithromycin (1,000 mg or 750 mg b.i.d.)
Trial: 9039532
Drug: Low-dose clarithromycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose clarithromycin (1,000 mg or 750 mg q.d.)
Trial: 8176095
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of atenolol once a day
Trial: 8176095
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of controlled-release metoprolol once a day
Trial: 3283918
Drug: Al-Mg antacids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al-Mg antacids (one tablet four times daily; acid-neutralizing capacity, 120 mmol/day) + pirenzepine (50 mg twice daily)
Trial: 3283918
Drug: Al-Mg antacids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al-Mg antacids (one tablet four times daily; acid-neutralizing capacity, 120 mmol/day) + pirenzepine placebo
Trial: 3283918
Drug: Antacid placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid placebo + pirenzepine (50 mg twice daily)
Trial: 3283918
Drug: Antacid placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid placebo + pirenzepine placebo
Trial: 3283918
Drug: Antacid placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid placebo
Trial: 28069089
Drug: Test meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test meal with 19-mg (all-E)-LYC from tomato paste
Trial: 28069089
Drug: Test meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test meal with 19-mg (all-E)-LYC from tomato paste plus 500-mg calcium carbonate
Trial: 16611682
Drug: Oral saline
RxNorm normalized name: Walgreens Phosphate Oral Saline Laxative SF Solution (Cherry)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral saline hydration (1 g/10 kg of body weight/day for 2 days before the procedure)
Trial: 16611682
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline hydration (0.9% saline at a rate of 15 ml/kg for 6 h before the procedure)
Trial: 16611682
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline hydration plus theophylline (5 mg/kg per os 1 h before the procedure)
Trial: 16611682
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline hydration plus furosemide (3 mg/kg intravenously just after the procedure)
Trial: 15478160
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate (maximum 1,500 mg/day)
Trial: 11505880
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose dexamethasone (100 mg stat, 16 mg every 6 hours for 48 hours)
Trial: 320955
Drug: Nonspecific therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonspecific therapy
Trial: 24708480
Drug: Melatonin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (50 mg infusion intra-operatively, 10 mg orally for the first three nights post-surgery)
Trial: 22285168
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg per day
Trial: 22285168
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (cisplatin 75 mg/m2 plus docetaxel 75 mg/m2 or gemcitabine 1250 mg/m2)
Trial: 17639157
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of multimixture added to school meals
Trial: 15778243
Drug: Etanercept treatment
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept treatment for 6 weeks
Trial: 15778243
Drug: Etanercept treatment
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept treatment for 24 weeks
Trial: 11870097
Drug: Alternative medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative medicine treatments (specific interventions not detailed)
Trial: 11870097
Drug: Randomized trials
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized trials of alternative medicine
Trial: 8726297
Drug: Mianserin, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin, 120 mg/day
Trial: 1872019
Drug: Yeast recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast recombinant pre‐S2 + S vaccine (12, 24 or 48 micrograms)
Trial: 1872019
Drug: Yeast recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast recombinant pre‐S2 + S vaccine
Trial: 26950692
Drug: Psychoanalytic psychotherapy
RxNorm normalized name: PSYCHOANALEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoanalytic psychotherapy (PPT) for 2 years of weekly sessions
Trial: 26950692
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) for 5 months
Trial: 22458939
Drug: AZD9668 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9668 60 mg bid
Trial: 22458939
Drug: AZD9668 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9668 5 mg bid
Trial: 22458939
Drug: AZD9668 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9668 20 mg bid
Trial: 19543000
Drug: granisetron 1
RxNorm normalized name: granisetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: granisetron 1 mg
Trial: 17380590
Drug: Duloxetine 20
RxNorm normalized name: duloxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 20 mg, 40 mg, and 60 mg single doses
Trial: 17380590
Drug: Duloxetine 20
RxNorm normalized name: duloxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 20 mg and 40 mg twice-daily for 5 days
Trial: 17371357
Drug: Topiramate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (50 mg)
Trial: 15450676
Drug: Ketamine (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.12 mg bolus followed by 0.5 mg/kg over 60 min)
Trial: 11408234
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg intravenous
Trial: 9818104
Drug: 5-HT2 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5-HT2 antagonist (sarpogrelate hydrochloride, 300 mg a day po)
Trial: 9818104
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (5-HT2 antagonist with SGBs)
Trial: 772172
Drug: Thioridazine treatment
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioridazine treatment (n=23)
Trial: 772172
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (n=22)
Trial: 31947853
Drug: Isomaltulose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomaltulose (50 g)
Trial: 25515398
Drug: Sucrose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (50 g)
Trial: 30844048
Drug: Non-febuxostat (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-febuxostat (conventional therapy with lifestyle modification)
Trial: 28709022
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy skills-based intervention
Trial: 23708056
Drug: L-arginine (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (9 g daily for 6 months)
Trial: 21167859
Drug: HB‐AS02 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB‐AS02 vaccine (two doses given one month apart)
Trial: 21167859
Drug: Licensed conventional
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licensed conventional recombinant hepatitis B vaccine (HBVAXPRO™; two doses)
Trial: 21167859
Drug: HB‐AS02 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB‐AS02 vaccine (single booster dose)
Trial: 21167859
Drug: Licensed conventional
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licensed conventional recombinant hepatitis B vaccine (single booster dose)